AEON Biopharma Says Is Aligned With FDA On Next Steps For 351(k) Regulatory Pathway To Approval For ABP-450 As A Biosimilar Utilizing BOTOX As The Reference Product
AEON Biopharma Says Is Aligned With FDA On Next Steps For 351(k) Regulatory Pathway To Approval For ABP-450 As A Biosimilar Utilizing BOTOX As The Reference Product
AEON生物製藥表示，與FDA在ABP-450作爲生物類似藥物，採用BOTOX作爲參比品的351(k)監管途徑獲得批准的下一步工作取得一致。
AEON Biopharma Says Is Aligned With FDA On Next Steps For 351(k) Regulatory Pathway To Approval For ABP-450 As A Biosimilar Utilizing BOTOX As The Reference Product
AEON生物製藥表示，與FDA在ABP-450作爲生物類似藥物，採用BOTOX作爲參比品的351(k)監管途徑獲得批准的下一步工作取得一致。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。